May 14, 2022

Assembly Biosciences Reports Incentive Grants Under Nasdaq Listing Rule 5635 (c) (4)

SOUTH SAN FRANCISCO, Calif., January 7, 2022 (GLOBE NEWSWIRE) – Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapies targeting hepatitis B virus (HBV) and ‘other viral diseases, today announced the granting of stock options to two new employees to purchase a total of 7,000 common shares of the Company with an exercise price of $ 2.45 per share, the closing price of the ordinary shares of Assembly Bio on January 3, 2022. Stock options were granted as material incentives to new employees to accept offers of employment from the Company.

Stock options have a ten-year term and vest over four years, with one-quarter vesting on the first anniversary of the grant date and the remaining three-quarters vesting in approximately equal monthly installments. The stock options are, in all cases, subject to the continuous service of new employees with Assembly Bio until the applicable vesting dates and to the acceleration in the event of the occurrence of certain events as defined in the allocation agreements attesting to stock options. None of the new employees are members of senior management.

The stock options were granted outside of the stock incentive plans approved by the shareholders of Assembly Bio in accordance with the 2020 Assembly Bio incentive plan. The stock option grants have been approved by the Compensation Committee of the Board of Directors of Assembly Bio, which is composed entirely of independent directors, as an important incentive to take up office at Assembly Bio in accordance with to Nasdaq listing rule 5635 (c) (4), which requires this public announcement.

About Assembly Biosciences
Assembly Bio is a clinical-stage biotechnology company committed to bringing end-to-end, curative therapies to the 270 million people living with hepatitis B virus (HBV) around the world. A pioneer in the development of a new class of potent oral nucleus inhibitor drug candidates, Assembly Bio’s approach aims to break the complex cycle of HBV viral replication to free patients from lifelong therapy. Assembly Bio’s strategy includes a leading portfolio of more potent next-generation baseline inhibitors, proof-of-concept combination studies for HBV cure, and research programs focused on discovering additional novel antiviral mechanisms. for HBV and other viral diseases. For more information visit assemblybio.com.

Contacts
Bio Assembly
Lauren Glaser
Senior Vice-President, Investor Relations and Corporate Affairs
(415) 521-3828
lglaser@assemblybio.com


Source link